Minivelle (Estradiol) Patent Expiration, LOE Window & CMS Spending

Minivelle (Estradiol) by Noven: FDA Orange Book core substance LOE 2030-07-04, 4 AB generics, $3.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNoven
FDA Application & PathwayN203752 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2030-07-04
Last Listed Patent or Exclusivity Date2030-07-04
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$3.6M
2024 Medicare Part D Spend$1.3M
2024 Medicaid Spend$2.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel